Dupilumab in Paediatric Netherton Syndrome: Two Case Reports and a Review of the Literature
ABSTRACT Netherton Syndrome (NS) is a rare genodermatosis characterised by a triad of ichthyosiform erythroderma, an atopic diathesis, and trichorrhexis invaginata, for which no effective management is currently approved in Australia. Dupilumab has demonstrated considerable effectiveness in the treatment of atopic conditions in the paediatric ...
Jacqueline Tu +5 more
wiley +1 more source
Molecular detection and genotyping of human herpes virus 8 in blood donors in Congo
Objectives. Human herpesvirus 8 (HHV8) is rarely studied in Congo, despite its prevalence in Africa. Among healthy individuals, HHV-8 does not always lead to a life-threatening infection; however, in immunocompromised individuals, it could lead to more severe disease.
Patrina Joseph Iloukou +6 more
openaire +3 more sources
ABSTRACT Among bacteria that are associated with the development and/or exacerbation of allergic/atopic diseases, several have been described to produce IgE‐binding components. However, only one bacterial protein, Bac s 1, is currently listed in the official database of the World Health Organization/International Union of Immunological Societies (WHO ...
Uta Jappe +24 more
wiley +1 more source
Human Herpes Virus 8 and Kaposi's Sarcoma: A Review.
Kaposi's Sarcoma (KS) was first described one century ago as a disease occurring in elderly men manifested as an indolent cutaneous form. After the onset of human immunodeficiency virus type I (HIV-1) infection, KS became epidemic which, in association with HIV, presented as an aggressive, systemic disease.
, Bahia, , Brites
openaire +1 more source
Protective role of Galectin‐3 in prion disease through regulation of microglial PrPSc uptake
Galectin‐3 (Gal3) is induced in reactive microglia during prion disease and promotes microglial uptake of PrPSc. Gal3 deficiency reduces prion sequestration and accelerates disease progression, revealing a protective role for Gal3. Abstract Microglia constitute a major innate defense mechanism against prion infection; however, the molecular pathways ...
Natallia Makarava +8 more
wiley +1 more source
Herpetic infections in humans: modern approaches to etiopathogenetic therapy
Background. Viruses of the Herpesviridae family are DNA-containing viruses prone to latent lifelong persistence in various tissues of the body after primary infection. According to WHO, 64% of people in the world under the age of 50 are infected with the
D. S. Sukhanov +4 more
doaj +1 more source
Novel approaches for drug development against chronic primary pain: A systematic review
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus +5 more
wiley +1 more source
Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu +6 more
wiley +1 more source
Long Non‐Coding RNA, Like NEAT1 and MALAT1, in Asthma: Mechanisms and Therapeutic Potential
Long non‐coding RNA, like NEAT1 and MALAT1, is emerging as a regulator of asthma‐related inflammation, airway remodelling, viral responses and cell death pathways, and are promising targets for future therapeutics. ABSTRACT Asthma affects millions worldwide. Long non‐coding RNA (lncRNA) are emerging as important factors in the pathophysiology of asthma
Ashlyn Poole +4 more
wiley +1 more source
Human herpes virus 8-positive germinotropic lymphoproliferative disorder: first case diagnosed in the UK, literature review and discussion of treatment options. [PDF]
Ghoneima A, Cooke J, Shaw E, Agrawal A.
europepmc +1 more source

